# Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

> **NCT02203253** · PHASE3 · COMPLETED · sponsor: **China Medical University, China** · enrollment: 642 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Placebo for thalidomide
- **DRUG:** Palonosetron and Dexamethasone

## Key facts

- **NCT ID:** NCT02203253
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-07
- **Final completion:** 2016-08
- **Target enrollment:** 642 (ACTUAL)
- **Last updated:** 2016-08-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203253, "Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02203253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*